Der interventionelle Vorhofohrverschluss: eine Alternative zur oralen Antikoagulation

Zusammenfassung

Die orale Antikoagulation ist der Standard zur Prävention von Embolien bei Patienten mit Vorhofflimmern. Der interventionelle Vorhofohrverschluss ist eine Alternative zur oralen Antikoagulation bei Patienten mit Vorhofflimmern und Kontraindikationen oder Unverträglichkeiten einer oralen Antikoagulation, insbesondere bei klinisch relevanten Blutungen. Die Sicherheit des Verfahrens hat in den letzten Jahren erheblich zugenommen. Mehrere große randomisierte Studien vergleichen aktuell die Effektivität und Sicherheit der oralen Antikoagulation und des interventionellen Vorhofohrverschlusses.

Abstract

Oral anticoagulation is the current standard for preventing thromboembolism in patients with atrial fibrillation. Interventional left atrial appendage closure is an alternative to oral anticoagulation in patients with atrial fibrillation with contraindications to an oral anticoagulation, in particular after clinically relevant bleeding. The safety of the procedure has increased significantly over the last decade. Large randomized trials are currently investigating the efficacy and safety of oral anticoagulation and interventional closure of the left atrial appendage.

Schlüsselwörter

interventioneller Vorhofohrverschluss - orale Antikoagulation - Prävention - Embolien - Kontraindikationen

Keywords

oral anticoagulation - thromboembolism - contraindication - prevention - interventional left atrial appendage closure

• Literatur

• 1 Hindricks G, Potpara T, Dagres N. et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42: 373-498
• 2 Salmasi S, Loewen P, Tandun R. et al. Adherence to oral anticoagulants among patients with atrial fibrillation: a systematic review and meta-analysis of observational studies. BMJ Open 2020; 10: e034778
• 3 Omran H, Tsikas A, Sievert H. et al. A history of left atrial appendage occlusion with the PLAATO device. Interven Cardiol Clinics 2018; 7: 137-142
• 4 Freeman J, Varosy P, Price M. et al. The NCDR Left Atrial AppendageOcclusion Registry. J Am Coll Cardiol 2020; 75: 1503-1518
• 5 Reddy V, Sievert H, Halperin J. et al. Percutaneous left atrial appendage closure vs Warfarin for atrial fibrillation. A randomized trial. JAMA 2014; 312: 1988-1998
• 6 Osmancik P, Herman D, Neuzil P. et al. Left atrial appendage closure versus direct oral anticoagulants in high-risk patients with atrial fibrillation. J Am Coll Cardiol 2020; 75: 3122-3135
• 7 Freeman JV, Varosy P, Price MJ. et al. The NCDR Left Atrial Appendage Occlusion Registry. J Am Coll Cardiol 2020; 75: 1503-1518
• 8 Hildick-Smith D, Landmesser U, Camm A. et al. Left atrial appendage occlusion with the AmplatzerTM AmuletTM device: full results of the prospective global observational study. Eur Heart J 2020; 41: 2894-2901
• 9 Galea R, De Marco F, Meneveau N. et al. Amulet or Watchman Device for Percutaneous Left Atrial Appendage Closure: Primary Results of the SWISS-APERO Randomized Clinical Trial. Circulation 2022; 145: 724-738
• 10 Lakkireddy D, Thaler D, Ellis C. et al. Amplatzer Amulet Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis (Amulet IDE). Circulation 2021; 144: 1543-1552
• 11 Kar S, Doshi S, Sadu A. et al. Primary Outcome Evaluation of a Next-Generation Left Atrial Appendage Closure Device Results from the PINNACLE FLX Trial. Circulation 2021; 143: 1754-1762
• 12 Lakkireddy D, Thaler D, Ellis C. et al. Amplatzer Amulet Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis (Amulet IDE). Circulation 2021; 144: 1543-1552
• 13 Dukkipati S, Kar S, Holmes D. et al. Device related thrombus aufter left atrial appendage closure. Incidence, Predictors, and Outcome. Circulation 2018; 138: 874-885
• 14 Sedaghat A, Vij V, Al-Kassou B. et al. Device related thrombus after left atrial appendage closure. Data on thrombus characteristics, treatment strategies, and clinical outcomes from the EUROC-DRT-Registry. Circ Cardiovasc Interv 2021; 14: 544-553
• 15 Flores-Umanzor E, Cepas-Guillen P, Arzamendi D. et al. Rationale and design of a randomized clinical trial to compare two antithrombotic strategies after left atrial appendage occlusion: double antiplatelet therapy vs. apixaban ADALA study. J Interv Card Electrophysiol 2020; 59: 471-477
• 16 Holmes D, Reddy V, Buchbinder M. et al. The assessment of Watchman device in patients unsuitable for oral anticoagulation ASAP TOO trial. Am Heart J 2017; 189: 68-74
• 17 Wazni O, Boersma L, Heleay J. et al. Comparison of Anticoagulation with Left Atrial Appendage Closure after AF Ablation: Rationale and Design of the OPTION randomized trial. Am Heart J 2022; 251: 35-42